A review of the literature was conducted to investigate the importance to offspring of in utero and breast milk polychlorinated biphenyl ( PCB ) exposure. All reports that we could identify ( n = 25 ) were included, representing 16 study populations. Tissue -specific PCB concentrations in human placenta, breast milk, maternal blood and cord blood were compared to determine accumulation ratios between tissue compartments. On a lipid basis, the highest concentration of PCB in placenta ( 5027 ng / g fat ) was 2.8 times higher than the highest concentration of PCB in breast milk ( 1770 ng / g fat ) . While there are limitations with regard to quantitation methods and statistical methods utilized by the reviewed studies, our results suggest that PCBs may be capable of crossing the placenta to a greater extent than previously believed. Future studies of PCB body burden in the perinatal period should include placenta, breast milk, maternal and cord blood specimens. In order to compare PCB concentrations in various tissues and with other studies, concentrations should be determined on a lipid basis.
Introduction
Polychlorinated biphenyls (PCBs ) and other halogenated aromatic hydrocarbons are ubiquitous environmental contaminants that accumulate in lipid -rich body tissues. Produced in the United States until 1977 (Laden et al., 1999 ) , PCBs are highly resistant to degradation, persist in animal and environmental reservoirs, and ascend the food chain, depositing in human tissues. Research suggests that PCB exposure in utero or during infancy is associated with lowered birth weight and gestational age Taylor et al., 1984 ) , intellectual impairment (Jacobson and Jacobson, 1996 ) , and delayed development (Guo et al., 1994 ) .
Human PCB exposure can occur through environmental accidents, dietary intake, and in utero to unborn children (Rappolt and Hale, 1968; Polishuk et al., 1977; Brown et al., 1994; Guo et al., 1994; Stewart et al., 1999 ) . PCBs accumulate in adipose tissue, blood lipids, and breast milk, and evidence indicates that this class of xenobiotics travels with the lipid components of blood ( VLDL, LDL, HDL, and chylomicron remnants ) and likely gains access to the many tissue compartments of the human body by utilizing the lipoprotein lipase mechanism ( Spindler-Vomachka et al., 1984; Gallenberg and Vodicnik, 1987; Soues et al., 1989; Borlakoglu et al., 1990a,b; Laden et al., 1999 ) . Differences in the lipid content of tissue compartments affect the distribution of PCBs. As the lipid content of breast milk is high, around 45 g /l (Diem, 1962) , it is generally believed that the highest degree of newborn exposure to PCBs and other lipophilic xenobiotics is through the ingestion of contaminated breast milk. Eyster and Kimbrough ( 1983 ) showed that mothers exposed to polybrominated biphenyls (PBBs ), which closely mimic the behavior of PCBs, had breast milk concentrations over 100 times the quantity found in maternal serum; however these values are uncorrected for lipid concentration. PCB studies have similarly reported higher concentrations of PCBs in breast milk than in maternal blood Rogan et al., 1986; Koopman -Esseboom et al., 1996 ) .
Our objective was to review the published literature and to compare the relative lipid -based ratios of PCB accumulation via multiple perinatal exposure routes, with particular attention to in utero and breast milk exposures.
Methods
A search of the MEDLINE and TOXLINE literature on perinatal PCB studies was conducted to assess the broad range of PCB concentrations in various human tissues. Twenty-five publications on 16 study populations were reviewed and their tissue -specific PCB concentrations were recorded. The reported concentrations from each study were grouped by tissue compartment. In nine instances, multiple publications analyzed members of the same data set. For our analysis, only one set of results from each study population was used. We selected the publication that reported values for the largest proportion of the study population (the largest sample size ) . When multiple publications utilized the same proportion of the study population, the publication that reported the highest tissue -specific PCB concentrations was selected.
To determine the PCB accumulation ratio between various tissue compartments, a lipid -based ratio was calculated for the concentration of PCB (in units of nanogram PCB per gram fat ) between compartments. Accumulation ratios were calculated within study populations. For example, to calculate the placenta -to -maternal blood ratio, a ratio for population A was calculated using data from population A only; a separate ratio was calculated for population B.
PCB quantitation methods vary greatly. Methods utilized by the reviewed studies include packed column gas chromatography (PCGC ) ( Kodama and Ota, 1980; Jacobson et al., 1984; Rogan et al., 1986; Krauthacker, 1992 , Czaja et al., 1998 ) and congener -specific or capillary column gas chromatography (CCGC ) ( Polishuk et al., 1977; Janousek et al., 1994; Schlebusch et al., 1994; Bosse et al., 1996; Dewailly et al., 1996; KoopmanEsseboom et al., 1996; Kostyniak et al., 1999; Kivirianta et al., 1998; Lanting et al., 1998a,b; Laden et al., 1999 Table 1 . We numerically equated specific gravity with density since the maximum density of water, the reference substance, is 1 g/ ml (Diem, 1962 ) .
The publications reviewed in this analysis reported either median or mean values. We cannot adjust for these differences in parameters of central tendencies that result from skewed distributions.
Results
The concentrations of PCBs by tissue compartment are reported in Table 2 . The middle column shows the concentration of PCB in the tissue converted to a lipid basis ( nanogram PCB per gram lipid ). The range of tissue concentrations of PCBs reflects differences in the populations sampled and the different quantitation and statistical methods employed in analysis. Some concentrations represent populations where there was no known exposure event Ð``unexposed''Ð (Bosse et al., 1996) while others represent``exposed'' populations, for example those living near a highly polluted industrial site (Schlebusch et al., 1994 ) . Figure 1 shows the range of median and mean lipidbased PCB concentrations across studies that reported total PCBs in various tissues. Nine studies determined PCB concentrations in breast milk, six in maternal blood components, five in cord blood components, four in placental tissue, and one each for amniotic fluid, uterine muscle, maternal adipose tissue, fetal and stillborn adipose tissue, non-pregnant adult and``Yusho'' adipose tissue. On a lipid basis, the highest concentration of PCB in placenta ( 5027 ng /g fat ) was 2.8 times higher than the highest concentration of PCB in breast milk (1770 ng /g fat ) .
Lipid -based ratios of accumulation between tissue compartments are presented in Table 3 . PCB concentrations in placental tissue range from 0.13 to 1.80 times the concentration in maternal blood (three studies ). The ratios calculated for the study population of Rogan et al. (1986 ) indicate that cord blood PCB concentrations in their study population were twice as high as placental values when examined on a lipid basis. The cord -to -maternal bloodbased ratios of four studies demonstrate that placental transfer of PCBs occurs and suggest that cord blood component concentrations can be at least as high as 60% of maternal levels (range: 0.59± 1.1 ). The ratios of cord blood component concentrations to breast milk concentrations range from 0.35 to 1.36 ( four studies ), whereas the ratios of maternal blood component concentrations to breast milk concentrations in four studies range from 0.60 to 1.79 ( Table 3 ) .
Discussion
The purpose of this review was to examine the published literature and compare accumulation gradients of multiple perinatal exposure routes. Our analysis suggests that, when assessed on a lipid basis, placental transfer of PCBs seems to be underestimated as a source of fetal exposure.
PCBs are stored in tissues that are high in lipids. As the percentage of lipid varies from tissue to tissue, PCB content follows patterns of fat content. Determination of tissue PCB concentrations, therefore, should be performed on a lipid basis. This permits comparison of the contaminant concentrations in different organs and tissues within the body and allows for comparison with exposure levels of different populations reported by other studies. It is for this reason that we converted tissue -specific PCB concentrations to a lipid basis. For these conversions, we assumed that blood is typically 0.5% fat, placenta 1± 1.5%, and milk 1 ±6% ( Rogan et al., 1986 ) .
We were surprised by the accumulation ratios of PCB in placenta to maternal blood ( Table 3 ) . The minimum value of 0.13 would lend support to the common assumption that placental storage of PCBs is relatively low. On the other hand, the ratios calculated for Polishuk et al. ( 1977 ) and Rogan et al. ( 1986 ) suggest that PCBs accumulate in the placental tissue. Table 2 and Figure 1 illustrate the wide range of reported placental concentrations of PCBs. The``unexposed population'' studied by Bosse et al. (1996) yielded higher concentrations than the population studied by Schlebusch et al. (1994 ) , which resided in a highly polluted industrial area in the former German Democratic Republic. Polishuk et al. ( 1977 ) , Rogan et al. (1986 ) , and Bosse et al. (1996 ) report placental concentrations ( range: 800 ±5027 ng /g fat ) that are 1.24 times higher than 8 of the 10 breast milk concentrations when compared on a lipid basis. Assuming a placental weight of 550 g ( Diamant et al., 1982 ) , a fat content of 1.25% (Table 1) , and an average PCB concentration in placental fat of 1000 ng /g fat, a placenta would contain about 6.9 g PCB.
The ratio of PCB in newborn fat to placental fat is also suggestive of a high degree of placental transfer (73.5% of the concentration in placental fat, Table 3 ) . The accumulation ratios of placenta to fetal blood and placenta to cord blood are between 51% and 71%. If one were to assume a newborn weight of 3300 g, a fat content of 12% in newborns (Diem, 1962 ) , and a PCB fat concentration of 700 ng /g fat, a newborn would have a burden of 277 g PCB. Thus, as the fetus increases in mass during the pregnancy period, it can catch up to and surpass the placental burden of PCB (6.9 g PCB ) . Therefore, transplacental exposure to PCBs may play a larger role than expected.
Due to the higher lipid content of breast milk, it is often assumed that the greatest source of PCB exposure to the infant in the perinatal period is via the ingestion of contaminated milk. Studies have shown breast -feeding to increase levels of PCBs in infants of exposed mothers. Lanting et al. (1998a ) reported that each additional week of full breast -feeding increased the plasma concentration of PCBs in 42-month -old children by 0.3%. Assuming first that milk consumption in infancy varies ( weeks 1± 2: 507 ml /day, weeks 3± 6: 630 ml /day, weeks 7± 10: 744 ml /day, Feer et al., 1980 ) , second, that human milk is 4.54% fat (Table 1 ) , and third, that the concentration of PCB is 550 ng /g fat in human milk, we would estimate a PCB intake of 1528 g in 13 weeks of nursing. As the percentage of fat in breast milk varies from 2.9% to 4.54% ( Diem, 1962 ) , our value may be an overestimate. If we considered the PCB burden in a 3 -month-old breast -fed infant with a weight of 5.9 kg, a 12% fat content (by weight ), a PCB concentration in whole blood of 3.6 ng /g blood ( Kodama and Ota, 1980) , a steady state of blood fat and body fat, and the conversion factors in Table 1 , we calculate an infant body burden of 823 g PCB. From delivery to 3 months, the infant increases its mass by a factor of 1.8 and has almost a threefold increase in total PCB body burden. As the difference of the estimated PCB burden at birth and at 13 weeks (546 g) is much lower than the estimated intake in that period (1528 g ), it appears that only a portion of the PCB content of breast milk is retained by the infant. The cord blood component to maternal blood component ratios additionally suggest that infant PCB levels may reach high levels as a result of in utero exposure alone; three out of the four accumulation ratios suggest that about 60% of PCB concentration in maternal blood can be detected in the fetal circulation.
The cord plasma to breast milk accumulation ratio of 0.35 calculated for the data of Koopman -Esseboom et al. (1996) is at least half that of the other three cord -to -milk ratios ( range: 0.71 ± 1.36) ( Table 3 ) . Their maternal blood component to milk ratios show a similarly low value. This is likely explained by differences in study populations, sampling procedures, and analytical methods. Cord blood infants at delivery 1.1 ppb 591 74 mean Kodama and Ota, 1980 ( PCGC ) Cord serum infants at delivery 2.0 ng / ml serum 576 198 mean Jacobson et al., 1984 ( PCGC ) Cord plasma human; voluntary mother ± infant pairs 0.5 ng / g plasma 147 207 mean; general community sample, congeners 118, 138, 153, 180 Koopman -Esseboom et al., 1996 ( CCGC with ECD ) Cord serum infants at delivery; not random sample < 4.27 ppb < 1264 744 median, 88% below quantitation limit Rogan et al., 1986 ( PCGC with ECD ) e a CCGC = capillary column gas chromatography, or congener -specific. b ECD = electron capture detection. The Dutch study (Koopman -Esseboom et al., 1996 ) sampled maternal blood during the last month of pregnancy ( 36th to 40th week ) and milk samples were collected the second week after delivery. In the Michigan study , maternal blood specimens were collected following delivery, whereas milk samples were collected 1 ± 16 weeks post -partum. Changes in plasma lipoprotein profiles during pregnancy could explain this apparent inconsistency. Gallenberg and Vodicnik ( 1987 ) studied the change in PCB distribution with advancing pregnancy in rats. Blood levels of 2,4,5,2 H ,4 H ,5 H -hexachlorobiphenyl ( 6-CB ) decreased with advancing pregnancy until birth, when levels in the blood seem to peak. While this increase was not statistically significant, it could explain the discrepancy between the Dutch and Michigan studies. Collecting the blood sample before birth may result in lower PCB levels in the blood, yielding a smaller maternal plasma -to -milk ratio. Regardless, the accumulation ratios confirm that breast milk is a major source of PCB exposure to newborn children.
The accumulation of PCBs in maternal blood ranges from 60% to 1.79% of the concentrations detected in breast milk samples. Kodama and Ota (1980) , Jacobson et al. ( 1984 ) , and Koopman -Esseboom et al. (1996 ) obtained maternal blood samples at delivery but obtained breast milk samples up to 4 months post -partum (Tables 2 and 3 ). These ratios suggest that, while breast milk is a major vehicle for infant exposure to PCBs while nursing, levels in maternal blood at birth can exceed those in milk.
The relatively small number of studies, the diverse populations they represent, and the dissimilar sampling procedures and analytical methods compared in this review prohibit us from drawing definite conclusions about the distribution of PCBs in the perinatal period. Additionally, quantitation limits and methods of statistical analysis (mean vs. median ) vary from study to study. The results do suggest, however, that PCB transfer across the placenta may play a substantial role in fetal exposure to halogenated aromatic hydrocarbons. Rappolt and Hale (1968) determined the concentrations of other chlorinated hydrocarbon residues (p,p H -DDE and p,p H -DDT ) in human tissues. Though their sample size was small, they found placental p,p H -DDE concentrations close to cord blood concentrations, suggesting a high degree of placental transfer.
The publication dates of studies included in this review span 22 years. During this time, there have been significant advances and refinements in analytical laboratory methods. Earlier studies utilized PCGC in quantifying PCB tissue concentrations ( e.g. Jacobson et al., 1984; Krauthacker, 1992 ) , while more recent studies use congener-specific CCGC ( e.g. Janousek et al., 1994; Dewailly et al., 1996; Lanting et al., 1998b; Kostyniak et al., 1999 ) . While these differences in quantitation techniques may influence the 0.60 a``+ '' indicates that the sample size for the numerator and denominator is at least as large as``n''. b Assumes placenta 1 ± 1.5% fat ( Rogan et al., 1986 ) . comparability of the studies, 10 of these 16 studies utilized CCGC ( Table 2 ) and the accumulation ratios calculated in our analysis were calculated using tissue concentrations within the same study. Figure 1 indicates that, with the exception of breast milk and post -partum maternal blood, CCGC, the preferred method, was used in PCB quantitation at both the high and low end of the concentration ranges; PCGC tended to fall in the middle of the ranges. The ratios still suggest that placental transfer of PCBs occurs to an appreciable extent.
Very few published studies determine placental concentrations of PCBs. It is common to measure only maternal blood, cord blood, and /or breast milk concentrations. The small number of placental studies that we were able to identify testifies to this; more research remains to be conducted. We recommend that future studies of the body burden of halogenated aromatic hydrocarbons in the perinatal period include analysis of placental tissue, breast milk, and maternal and cord blood. We also suggest that future research endeavors report both the median and geometric means of contaminant concentrations, measures which ( versus arithmetic means ) are not affected by outliers. Finally, we recommend that tissue concentrations be determined on a lipid basis, as accumulation is highly dependent on the lipid content of the tissue. These recommendations will enable comparison of concentrations between various tissue compartments and with results from other studies.
